Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William R Markesbery

Showing results (81-90 of 107) with videos related to

Pageof 11
Sort By:
Journal of Alzheimer'S Disease : JAD|January 23, 2009
Acetylcholinesterase inhibitor treatment is associated with relatively slow cognitive decline in patients with Alzheimer's disease and AD + DLBPeter T Nelson, Richard J Kryscio, Erin L Abner, et al.
Neuroscience Letters|November 18, 2008
Alzheimer's-type neuropathology in the precuneus is not increased relative to other areas of neocortex across a range of cognitive impairmentPeter T Nelson, Erin L Abner, Stephen W Scheff, et al.
Journal of Neurology|October 2, 2009
Low sensitivity in clinical diagnoses of dementia with Lewy bodiesPeter T Nelson, Gregory A Jicha, Richard J Kryscio, et al.
Antioxidants & Redox Signaling|November 26, 2009
NOX activity is increased in mild cognitive impairmentAnnadora J Bruce-Keller, Sunita Gupta, Taryn E Parrino, et al.
Journal of Neurochemistry|December 3, 2008
Effects of short-term Western diet on cerebral oxidative stress and diabetes related factors in APP x PS1 knock-in miceChrista M Studzinski, Feng Li, Annadora J Bruce-Keller, et al.
Journal of Proteomics|July 6, 2011
Proteomic identification of specifically carbonylated brain proteins in APP(NLh)/APP(NLh) × PS-1(P264L)/PS-1(P264L) human double mutant knock-in mice model of Alzheimer disease as a function of ageRukhsana Sultana, Renã A S Robinson, Fabio Di Domenico, et al.
Proteomics|September 29, 2011
Proteomic analysis of brain proteins in APP/PS-1 human double mutant knock-in mice with increasing amyloid β-peptide deposition: insights into the effects of in vivo treatment with N-acetylcysteine as a potential therapeutic intervention in mild cognitive impairment and Alzheimer's diseaseRenã A S Robinson, Gururaj Joshi, Quanzhen Huang, et al.
Nucleic Acids Research|April 12, 2007
Identification and characterization of OGG1 mutations in patients with Alzheimer's diseaseGuogen Mao, Xiaoyu Pan, Bei-Bei Zhu, et al.
Alzheimer Disease and Associated Disorders|July 3, 2009
Comparison of recruitment efforts targeted at primary care physicians versus the community at large for participation in Alzheimer disease clinical trialsSarah A Carr, Roberta Davis, Diane Spencer, et al.
Neurobiology of Aging|June 14, 2005
Oxidative modification and down-regulation of Pin1 in Alzheimer's disease hippocampus: A redox proteomics analysisRukhsana Sultana, Debra Boyd-Kimball, H Fai Poon, et al.
Pageof 11

Showing results (81-90 of 107) with videos related to

Sort By:
Pageof 11
Journal of Alzheimer'S Disease : JAD|January 23, 2009
Acetylcholinesterase inhibitor treatment is associated with relatively slow cognitive decline in patients with Alzheimer's disease and AD + DLBPeter T Nelson, Richard J Kryscio, Erin L Abner, et al.
Neuroscience Letters|November 18, 2008
Alzheimer's-type neuropathology in the precuneus is not increased relative to other areas of neocortex across a range of cognitive impairmentPeter T Nelson, Erin L Abner, Stephen W Scheff, et al.
Journal of Neurology|October 2, 2009
Low sensitivity in clinical diagnoses of dementia with Lewy bodiesPeter T Nelson, Gregory A Jicha, Richard J Kryscio, et al.
Antioxidants & Redox Signaling|November 26, 2009
NOX activity is increased in mild cognitive impairmentAnnadora J Bruce-Keller, Sunita Gupta, Taryn E Parrino, et al.
Journal of Neurochemistry|December 3, 2008
Effects of short-term Western diet on cerebral oxidative stress and diabetes related factors in APP x PS1 knock-in miceChrista M Studzinski, Feng Li, Annadora J Bruce-Keller, et al.
Journal of Proteomics|July 6, 2011
Proteomic identification of specifically carbonylated brain proteins in APP(NLh)/APP(NLh) × PS-1(P264L)/PS-1(P264L) human double mutant knock-in mice model of Alzheimer disease as a function of ageRukhsana Sultana, Renã A S Robinson, Fabio Di Domenico, et al.
Proteomics|September 29, 2011
Proteomic analysis of brain proteins in APP/PS-1 human double mutant knock-in mice with increasing amyloid β-peptide deposition: insights into the effects of in vivo treatment with N-acetylcysteine as a potential therapeutic intervention in mild cognitive impairment and Alzheimer's diseaseRenã A S Robinson, Gururaj Joshi, Quanzhen Huang, et al.
Nucleic Acids Research|April 12, 2007
Identification and characterization of OGG1 mutations in patients with Alzheimer's diseaseGuogen Mao, Xiaoyu Pan, Bei-Bei Zhu, et al.
Alzheimer Disease and Associated Disorders|July 3, 2009
Comparison of recruitment efforts targeted at primary care physicians versus the community at large for participation in Alzheimer disease clinical trialsSarah A Carr, Roberta Davis, Diane Spencer, et al.
Neurobiology of Aging|June 14, 2005
Oxidative modification and down-regulation of Pin1 in Alzheimer's disease hippocampus: A redox proteomics analysisRukhsana Sultana, Debra Boyd-Kimball, H Fai Poon, et al.
Pageof 11